AKBA Akebia Therapeutics Inc.

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 in New York.

Wells Fargo Healthcare Conference

Erik Ostrowski, Chief Financial and Chief Business Officer, and Nik Grund, Chief Commercial Officer, will present on Thursday, September 4 at 8:00 AM EDT.

H.C. Wainwright Global Investment Conference

Mr. Ostrowski and Mr. Grund will participate in a fireside chat on Monday, September 8 at 12:00 PM EDT.

A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at  following the conferences.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
28/08/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 in New York. Wells Fargo Healthcare ConferenceErik Ostrowski, Chief Financial and Chief Business Officer, and N...

10h / 8m 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Avai...

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and (IRC), a leading comprehensive kidney care provider in the U.S., today announced the broad availability of Vafseo® (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients across all IRC clinics. ...

August 21, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and ...

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CA...

August 7, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Grow...

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston. A webcast of the presentation can be accessed through the “Investors” section of A...

August 6, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunct...

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a week CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL trial, conducte...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch